PROVIDENCE, R.I.--(BUSINESS WIRE)--Tivorsan Pharmaceuticals announced today that its academic collaborators – Professor Fallon and his research group at Brown University – have received a generous award from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). This award provides funding and support for the accelerated preclinical development of biglycan as a novel disease-modifying therapeutic for Duchenne Muscular Dystrophy (DMD). DMD is an unrelenting and progressive, genetic, muscle-wasting disorder that currently has no good treatment options.
